1. The Effect of Lactobacillus fermentum ME‐3 Treatment on Glycation and Diabetes Complications
- Author
-
Eric Boulanger, Axel Guilbaud, Brigitte Onraed, Céline Niquet-Léridon, Patrice Maboudou, Mike Howsam, Susanna Schraen, Sophie Lestavel, Frédéric J. Tessier, Anne Garat, Marc Fremont, Florian Delguste, Benoît Foligné, CHU Lille, Inserm, Institut Pasteur de Lille, Université de Lille, Lille Inflammation Research International Center (LIRIC) - U995, Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167, Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011, Lille Inflammation Research International Center - U 995 [LIRIC], IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483, UniLaSalle, Lille Neurosciences & Cognition (LilNCog) - U 1172, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE], Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD], Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille], Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS], Service de pathologie [CHU Lille], Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Transformations et Agro-ressources (UT&A), Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Impact de l'environnement chimique sur la santé humaine - ULR 4483 (IMPECS), and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
- Subjects
Glycation End Products, Advanced ,Male ,0301 basic medicine ,Limosilactobacillus fermentum ,Lactobacillus fermentum ,[SDV]Life Sciences [q-bio] ,Type 2 diabetes ,carboxymethyllysine ,Pharmacology ,Gut flora ,Kidney ,Weight Gain ,Diabetes Mellitus, Experimental ,law.invention ,Diabetes Complications ,03 medical and health sciences ,Probiotic ,law ,Glycation ,Diabetes mellitus ,medicine ,Animals ,furosine ,Glycated Hemoglobin ,030109 nutrition & dietetics ,diabetes ,biology ,business.industry ,Lysine ,Probiotics ,Diabetic mouse ,biology.organism_classification ,medicine.disease ,Lipids ,Gastrointestinal Microbiome ,030104 developmental biology ,glycation ,probiotics ,Liver ,Receptors, Leptin ,Steatosis ,business ,Food Science ,Biotechnology - Abstract
International audience; ScopeType 2 diabetes (T2D) induces organ damage associated with glycation, among other metabolic pathways. While therapeutic strategies have been tested to reduce the formation and impact of glycation products, results remain equivocal. Anti-diabetic therapies using probiotics have been proposed, but their effect upon glycation has not been reported. Here, the effects of the bacterial strain Lactobacillus fermentum ME-3 on glycation and T2D-related complications in a mouse model of T2D are investigated.Methods & ResultsWild-type LepRdb and diabetic LepRdb littermates receive a daily gavage of either water or the probiotic ME-3 strain (1010 CFU). Glycation markers, fructoselysine-derived furosine (FL-furosine) and carboxymethyllysine (CML), are quantified in four major organs and plasma using stable-isotope dilution LC–MS/MS. After 12 weeks of ME-3 treatment, diabetic mice gain less weight and exhibit an apparently improved glucose tolerance. The ME-3 treatment reduces median renal levels of FL-furosine in both genotypes by 12–15%, and renal and pulmonary free-CML in diabetic mice by 30% and 18%, respectively. Attenuated hepatic steatosis and an improved plasma lipid profile are also observed with treatment in both genotypes, while the gut microbiota profile is unchanged.ConclusionL. fermentum ME-3 has therapeutic potential for reducing the formation/accumulation of some glycation products in kidneys and attenuating some common diabetes-related complications.
- Published
- 2020
- Full Text
- View/download PDF